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1. Introduction 
Epithelial monolayers act as barriers to the movement of small solute molecules – including 
both inorganic ions and drugs – between body compartments. Ions traverse epithelial apical 
and basolateral membranes via a combination of tightly regulated ion-specific transporters 
and channels. Compromised function of any component leads to electrolyte and fluid 
imbalances resulting in morbidity and potentially, mortality. In the case of cystic fibrosis 
(CF) the defect lies in various genotypes that result in suboptimal synthesis, folding, 
transport, or gating of the CF transmembrane conductance regulator (CFTR; an anion 
channel that has other reported cellular functions). Many of the current therapies involve 
palliative interventions that address infections, inflammation, nutrition and mucus viscosity 
issues in patients. While these approaches have increased the life span of CF patients by 
reducing the rate of decline in lung functions or other health issues, none of them addresses 
the underlying cause of the disease at the cellular or tissue level, namely reduced anion 
conductance that sets the chemiosmotic driving force for both paracellular and transcellular 
fluid movement.  
Many recent studies focus on small molecule approaches to rescue some forms of CFTR that 
are defective with respect to folding, intracellular trafficking, or activity. Of particular note 
has been the identification of VX-770, a small molecule that restores CFTR activity in 
patients harboring the G551D mutation. Results of a phase 3 clinical trial showed that VX-
770 improved lung function by 10.5 percent over the placebo and achieved all secondary 
goals of the study (Accuroso et al., 2010). This is the first drug to show improvement in lung 
function in patients with the G551D mutation. Unfortunately, such profound effects of this 
drug have not been realized when tests were conducted with patients harboring other CFTR 
mutations. Other small molecules that may affect other forms of CFTR (e.g., ataluren for 
premature stop codons) are in the pipeline, although none appears to be as advanced as VX-
770. 
The idea of using small pore-forming peptides to treat various channelopathies has been an 
ongoing objective since identifying the pore-defining M2 transmembrane (TM) segment in 
the -subunit of the spinal cord glycine receptor (GlyR) Cl- channel in the early 1990’s 
(Reddy et al., 1993). The parent sequence, M2GlyR, is the pore-forming segment of the Cl- 
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selective human spinal cord glycine receptor. In Wallace et al., (1992), we first suggested that 
inserting exogenous Cl- channel-forming peptides into the apical membranes of airway 
epithelial cells of CF patients may aid in restoring the ability of these cells to secrete fluid. 
This was the rationale for developing synthetic Cl--conducting channel-forming peptides as 
potential therapeutic agents. We have since developed synthetic peptides that form pores 
with varying degrees of anion conduction and selectivity. A guiding goal has been the de 
novo generation of a pore that could be used as a general therapeutic for CF since it would 
not require genotyping of individual patients. This novel therapeutic intervention, which 
would provide a new conductance pathway for selected anions, lies midway between 
conventional drug therapy and gene therapy. The primary target tissue, airway epithelium 
is accessible to aerosolized formulations such that the therapeutic peptides could be 
delivered easily. 
The ideal therapeutic channel-forming peptide should: 1) have high aqueous solubility as 
a monomer; 2) have no detectable antigenicity; 3) bind to and then partition into 
biological membranes rapidly at low solution concentrations; 4) undergo supramolecular 
assembly in the membrane to form pores with measurable ion throughput; and 5) show 
physiologically relevant anion selectivity. All of these targeted outcomes have been 
achieved with the exception of the final goal, anion selectivity. In this regard, we are 
exploring distinct approaches to raise the permselectivity for Cl- (PCl) relative to both Na+ 
and K+.  
Cells exposed to our de novo peptides that form membrane pores appear to tolerate them 
well, with net anion flux controlled by the natural regulation of counter-ion transport 
and/or anion loading. Using a combination of peptide synthesis, electrophysiology, 
structural biology and computer simulations we are endeavoring to prepare highly anion-
selective channels. Numerous studies have been performed that switch anion to cation 
selectivity and vice-versa (see review-Keramidasa et al., 2004). Our studies targeting 
enhanced anion selectivity are novel and will yield a lead compound for treating CF as well 
as aid in our understanding of anion selectivity in channel proteins. The work is being 
accomplished by preparing sequences with rational alterations to the residues that dictate 
the chemical composition and structure of the pore. 
This chapter will review our extensive exploration of the permissible amino acid 
replacements in the M2GlyR sequence based on knowledge of Cl- binding motifs and 
channel architecture. Modifications to the channel forming peptides were based on a wealth 
of data obtained from the fields of inorganic chemistry, channel physiology, structural 
determinations and computer modeling. The channel-forming peptides discovered during 
this project are remarkable in several ways: 1) they are small and easily synthesized; 2) they 
are water soluble and can be delivered to membrane surfaces without added organic 
solvents; 3) most are predominantly monomeric in solution; 4) when inserted into 
membranes, all peptides are expected to be oriented in the same direction due to the highly 
positively charged N-terminus; 5) all assembled pores are composed with a parallel 
orientation of the helices; 6) functional ion conducting pores are formed that can provide 
information on various channel properties; and 7) the small size of the peptides and the 
assembled pores facilitate concerted efforts for structural analyses and computer modeling 
that can produce informative structures.  
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To our knowledge no other membrane/peptide system offers such flexibility for design and 
analysis. Many TM sequences have been and are being studied by others (Marsh, 1996). 
However, for the most part, incorporation into bilayers leads to a mixed orientation with 
helical dipoles present in both directions. Such mixing of dipole orientations is prevented in 
our oligo-lysine adducted M2GlyR peptide system. This review will describe our 
understanding of how these peptides form channels with a range of anion selectivity and 
conductance properties, through a combination of electrophysiology, biophysical structural 
studies and computer simulations.  
2. Current CF therapies 
While a number of therapies for CF are currently in development, many of the treatment 
options presently available to patients are palliative in nature, addressing one or more 
symptoms of the condition and acting to reduce the severity of these effects and their 
associated risks.  
Diet/nutritional supplements Proper diet and nutrition may reduce the impact and risk of 
CF-related conditions such as diabetes and osteoporosis. The lungs of CF patients appear to 
have fewer natural antioxidants than those without the condition, which may contribute to 
repeated infection and persistent inflammation. Patients may benefit from an increase in 
their intake of antioxidants through diet or supplements to fight this inflammation. Further 
promise may lie in drugs that work to build antioxidants in the lungs. AquADEKs® by 
Yasoo Health, Inc. is a vitamin supplement specifically formulated to meet the antioxidant 
needs of those with CF, and is commercially available. It has been shown to improve lung 
function, normalize vitamin levels in plasma and reduce neutrophilic inflammation (Sagel et 
al., 2011). 
Enzyme replacement therapies Pancreatic enzyme products work to increase the digestion 
and absorption of fats, proteins, and starches while promoting the absorption of certain 
vitamins in those with CF, who often suffer from malnutrition due to enzyme deficiencies. 
The U.S. Food and Drug Agency (FDA) has approved a number of these products, including 
Zennen® (Eurand Pharmaceuticals), Creon® (Abbott Laboratories) and Pancreaze™ (Ortho-
McNeil Pharmaceutical), while others, such as Pancrecarb® (DCI) and Ultrase® (Axcan 
Scandipharm) are still awaiting clinical trials. Liprotamase® (Alnara Pharmaceuticals) is a 
non-porcine pancreolipase enzyme therapy, which has completed a phase 3 clinical trial. 
However, the new drug application submitted by Alnara was rejected by the FDA on the 
grounds of insufficient data demonstrating the efficacy of the drug (Lowry, 2011). 
Antibiotics/anti-infectives Due to the increased risk of disease caused by the excess and/or 
viscous mucus that is characteristic of CF, patients are often treated with antibiotics to 
circumvent chronic infections, such as that of Pseudomonas aeruginosa. Antibiotics can be 
administered orally, intravenously, via inhalation through devices such as metered dose 
inhalers (MDIs), or through implanted devices such as a port or Peripherally Inserted 
Central Catheter (PICC) (Gibson et al. 2003). TOBI® (tobramycin solution for inhalation) and 
recently developed Cayston® (aztreonam solution for inhalation) are two approved and 
commonly prescribed antibiotics for patients with CF, and both are effective against  
P. aeruginosa. TOBI® is approved to treat P. aeruginosa infections by concentrating the 
delivery of the antibiotic to the airways. Developed by Novartis Pharmaceuticals and widely 
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used worldwide since its FDA approval in 1997, TOBI® has been successful in improving 
overall lung function while reducing hospital stays for CF patients (Cheer et al., 2003). TIP 
(TOBI® Inhalation Powder) is a new form of tobramycin that takes less time to administer 
via a Podhaler® and exhibits the same efficacy as the original formulation. It has been 
approved for use in Canada (http://www.pharmiweb.com/pressreleases/pressrel.asp? 
ROW_ID=23942 and http://www.novartis.com/newsroom /media-releases/en/2010/ 
1446760.shtml). Cayston® (formerly GS9310/11) by Gilead Sciences is a newly developed 
version of the antibiotic aztreonam lysine in aerosol form. It was approved by the FDA and 
has been available to CF patients since February of 2010 (http://www.accessdata.fda.gov/ 
scripts/cder/drugsatfda/ index.cfm?fuseaction=Search.DrugDetails).  
The macrolide antibiotic azithromycin (Pfizer, Inc.) has been shown, when administered 
orally, to fight P. aeruginosa infection and improve pulmonary function in CF patients aged 6 
years and older. Further studies are required to determine efficacy of prolonged treatment 
and in treating those under 6 years of age (Saiman et al., 2003). Further, azithromycin 
(Delete “the common antibiotic”) was shown in phase 3 trials to preserve healthy lung 
function in CF patients (Saiman et al., 2010). Several other anti-infective agents, which are 
presently being evaluated, are discussed in brief below. Mpex Pharmaceuticals has recently 
developed MP-376, an aerosol form of levofloxacin, used to treat P. aeruginosa infections in 
the lungs. Phase 3 trials are currently underway (http://www.mpexpharma.com/mp-
376.html). Insmed Incorporated recently completed phase 2 trials of Arikace™, a version of 
the FDA-approved antibiotic amikacin in a liposomal formulation that is inhaled using a 
nebulizer. It was shown in animal studies to decrease the pathogenicity of P. aeruginosa and 
has demonstrated success in permeating human sputum in the lungs. Phase 3 trials are set 
to begin in late 2011 (http://www.insmed.com/arikace.php). Bayer Schering 
Pharmaceuticals’ BAY Q3939, was developed as a new inhaled version of the drug 
ciprofloxacin to more effectively treat infections in air passages. Phase 2 trials for the drug 
are currently underway (http://clinicaltrials.gov/ct2/show/NCT00645788). 
Mucolytics/Airway-Rehydrating Agents Since viscous mucus build-up in the lungs can 
promote bacterial infections, many therapies are directed toward reducing the symptom by 
restoring the liquid necessary to hydrate the mucus or the underlying layer to facilitate 
expectoration (Pettit and Johnson, 2011) or, in the case of Pulmozyme® and other agents, to 
reduce mucus viscosity. Pulmozyme® by Genentech is a Dornase alfa (recombinant human 
deoxyribonuclease) treatment used to break down the DNA responsible for thickening 
pulmonary mucus and thus to reduce viscosity, promote mucus clearing, and ultimately 
restrict (delete “to”, replace “reduce” with “restrict”) the environment that supports 
bacterial growth. Approved in 1993 and introduced in 1994, Pulmozyme® is currently in use 
as a mucolytic for patients with CF and has been shown to increase lung function  
by about 6% and reduce the risk of infection by 27% (Fuchs et al., 1994; 
http://www.pulmozyme.com/hcp/prescribing-info.jsp#table1). Moli1901 by Lantibio 
stimulates alternative Cl- channels in order to compensate for the deficiencies of CFTR in the 
pulmonary epithelium of patients. In phase 2 European trials, Moli1901 was well tolerated 
in most patients (one participant experienced a transient decrease in pulmonary function). 
Those receiving treatment of 2.5 mg daily of inhaled Moli1901 showed significant 
improvement in lung function measured as forced expiratory volume in one second (FEV1; 
Grasemann et al., 2007).Initially promising, Denufosol, a P2Y2 agonist developed by Inspire, 
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was believed to rehydrate the airway surface liquid, bypassing the basic CFTR protein 
defect, producing improvement in pulmonary function (Kellerman et al., 2008). However, 
the most recent clinical trial found it to be without effect.  GS9411 by Gilead is an epithelial 
Na+ channel (ENaC) inhibitor, which blocks Na+ absorption in airways to reduce mucus 
dehydration. A phase 1 trial of GS9411 has been completed and the drug was shown to be 
safe and well tolerated (Sears et al., 2011; http://clinicaltrials.gov/ct2/show/ 
NCT00999531).  
An Australian clinical trial showed that a mist of hypertonic saline delivered via nebulizer 
twice daily for one year helped to improve lung function and reduce lung infections. The 
study included participants 6 years of age and older with mild or moderate lung disease 
(however, those with Burkholderia cepacia were not included in the study). The study tested 
two groups, one receiving “normal saline” solution at 0.9%, and the other receiving the 
“hypertonic saline” solution at 7% salt. While both groups showed improvement in 
pulmonary function during the study, those receiving hypertonic saline exhibited 
significantly greater improvement than those on normal saline. Elkins et al. (2006) reported 
that hypertonic saline also caused a reduction in exacerbations from the lungs, and 
Donaldson et al. (2008) hypothesized that this was due to the “protection” by hypertonic 
saline of non-obstructed airways from further mucus build-up and bacterial infection. 
Similarly, an inhaled version of mannitol was shown to help clear CF airways and 
improve pulmonary function by an average of 7.3% (FEV1) and forced airway flow by 
15.5%. Mannitol works by drawing water into the lungs osmotically and thus helping to 
clear mucus. No serious adverse side effects were observed and it appeared to be well 
tolerated by patients (Jaques et al., 2008; Bilton et al., 2011). Phase 3 trials have been 
completed and the therapy is currently being marketed in Europe, and Pharmaxis hopes 
to submit a new drug application for Bronchitol to the FDA 
(http://www.pharmaxis.com.au/assets/pdf/2010/15122010). 
Anti-Inflammatories Due to the recruitment of macrophages and neutrophils during 
rounds of bacterial infection, collateral damage to host airway cells by nuclear factor (NF)-
kappa B activation and elevated pro-inflammatory cytokines leads to scarring and fibrosis. A 
number of anti-inflammatory agents are currently being used or studied to determine their 
efficacy in reducing inflammation in the pulmonary passages of CF patients. The over-the-
counter drug, ibuprofen, taken orally twice daily at dosages adjusted to give peak plasma 
concentrations of 50 to 100 micrograms per milliliter, reportedly reduced the decline of lung 
function (Konstan et al., 1995). Oral N-acetylcysteine (PharrmaNAC, BioAdvantex Pharma, 
Inc.) was shown in clinical trials to reduce inflammation and increase pulmonary function 
by restoring glutathione in neutrophils. A phase 2 trial has completed enrolling subjects 
recently (Tirouvanziam et al., 2006; Atkuri et al., 2007). In a similar approach, inhaled doses 
of glutathione have completed phase 2 trials in Germany and data will be available in late 
2011 (Retsch-Bogart, 2007). A University of Massachusetts study was conducted to test the 
efficacy of adding the fatty acid docosahexaenoic acid (DHA) to fortify infant formula in 
reducing CF pathogenicity. This work is based on the observation that an imbalance in fatty 
acids can lead to inflammation. It is hypothesized that an increase in DHA can help reduce 
inflammation that occurs with CF-related imbalances. Results of the study will be available 
in 2011. Genzyme Corp., which has licensed the patent as a treatment for CF, is considering 
new and more effective means of delivering DHA (Freedman et al., 1999; 2004). KB001 
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produced by Kalobios Pharmaceuticals reduces local inflammation from the virulence factor 
of P. aeruginosa. P. aeruginosa uses the structure of its Type Three Secretion System (TTSS) to 
break through cellular membranes and release toxins. KB001 binds to the PcrV protein 
essential to TTSS and inhibits its activity, reducing pathogenicity and preserving the 
immune defense of the host against P. aeruginosa. Though KB001 may reduce pathogenicity 
of P. aeruginosa, thereby preventing inflammation, it does not appear to affect in vivo growth 
of the bacteria, and thus is not classified as an anti-infective (Baer et al., 2008; 
http://www.kalobios.com/kb_pipeline_001.php). A recent report showed that an inhaled 
phosphodiesterase type 5 inhibitor, sildenafil, increased Cl- transport in mice (Lubamba et 
al., 2011). Further research at the University of Wales suggested that sildenafil may assist in 
intracellular trafficking of the ΔF508-CFTR gene protein (Dormer et al., 2005). The 
corticosteroid, GSK SB 656933 manufactured by GlaxoSmithKline is an inhaled dose of 
fluticasone propionate used to treat lung inflammation was shown to be safe and  
tolerated in CF patients in phase 1 clinical trials (Lazar et al., 2011; 
http://www.clinicaltrials.gov/ct2/show/NCT00903201?term=656933&rank=5NLM 
Identifier: NCT00903201). The drug is currently used to reduce pulmonary inflammation in 
chronic obstructive pulmonary disease (COPD). 
Experimental CF Therapies Aside from gene therapy, some new experimental approaches 
are aimed at modifying the folding or translocation of the endogenous mutant CFTR 
proteins in order to generate a functional channel protein at the cell surface. Correcting these 
defects would re-establish transcellular flow of Cl-, Na+, and water to clinically relevant 
levels to provide appropriate airway surface liquid volume and composition 
(http://www.cff.org/treatments/Pipeline/).  
CF Gene Therapy is directed toward correcting the channelopathy by incorporating DNA 
that encodes for the full-length wild-type CFTR protein. Research suggests that CFTR gene 
expression is required at a mere 5% of the normal level in order to improve pulmonary 
function (Ramalho et al., 2002). There are a number of gene therapy protocols currently 
under investigation with the frontrunners discussed below.  
Compacted DNA (PLASmin®): (unbold. Inconsistent) One problem in developing a 
treatment for CF through gene therapy is that non-viral DNA must be condensed, which 
is commonly achieved through the use of polycations. However, this often results in a 
complex that is too large to cross the cellular membrane effectively and deliver DNA to 
the affected cells. Cleveland-based Copernicus Therapeutics, Inc. developed a compacted 
DNA/DNA nanoparticle therapy (PLASmin®) that decreases the volume of the complex 
by up to 1000-fold, to a single molecule small enough to permeate the membrane and 
nuclei of target cells. The complex contains only one copy of the DNA to be delivered, 
increasing the stability and efficacy of the treatment (Chen et al., 2007). In phase 1a trials, 
plasmid DNA nanoparticles with the gene responsible for encoding CFTR were applied 
intra-nasally with lysine peptides substituted with polyethylene glycol. About two-thirds 
of the participants in the study showed a significant improvement and results persisted 
for up to 6 days. No adverse side effects of considerable severity were observed as a result 
of the compacted DNA. However, this trial presented no demonstration of gene 
expression (Konstan et al., 2004). More recently, Copernicus has experienced greater 
success with the level and duration of CFTR expression in animal models 
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VX-770 (Ivacaftor; Vertex Pharmaceuticals) is a novel therapy that seeks to augment CFTR 
activity in patients harboring the G551D mutation. This small molecule is a CFTR 
“potentiator” that increases function of faulty CFTR proteins by holding the defective 
channels in the open conformation. This treatment has completed phase 1 and phase 2 trials, 
which have shown efficacy in reducing sweat Cl- concentrations and increasing nasal 
potential difference measures as well as improvements in general lung health. VX-770 
replicated these results in two phase 3 trials – one for ages 12 and above (adult) and one for 
ages 6-11 (child). Both trials showed relevant increases in FEV1 of 10.6% and 12.5% for each 
age group respectively over the placebo groups. VX-770 also helped patients in the trials 
gain weight – nearly 7 pounds on average for the adult trial and about 8 pounds for the 
children’s trial. Finally, the phase 3 trials also showed increases in general lung health, 
indicated the treatment was well tolerated, and demonstrated lower sweat Cl- levels. This 
closer to normal Cl- range is very important to note as it provides empirical evidence that 
VX-770 is effectively treating the cause of CF and not just its symptoms. Vertex plans to 
submit a new drug application (NDA) to the FDA in late 2011 for VX-770 (Sheridan, 2011). 
VX-809 in conjunction with VX-770: VX-809 is a novel small molecule CFTR “corrector” 
being developed by Vertex Pharmaceuticals that seeks to augment channel activity in CF 
patients with the ΔF508 CFTR mutation when used in conjunction with VX-770. The ΔF508 
mutation affects 87% of CF patients in the United States (48% of patients have both mutant 
alleles while 39% have one). Misfolding of the mutated protein interferes with cytosolic 
trafficking such that the protein never reaches the apical membrane, precluding any anion 
secretion. VX-809 partially corrects the defect by promoting the trafficking of CFTR proteins 
to its proper location in the apical membrane. ΔF508 CFTR has a reduced open probability. 
Thus, VX-809 is paired with VX-770, the CFTR “potentiator”, in the hopes of increasing total 
protein function for maximum effect on the disease. A phase 2 trial testing various dose 
combinations of the two compounds met its primary endpoints of safety and efficacy in the 
first part of the trial. Patients harboring the ΔF508 mutation were given VX-809 or a placebo 
for 14 days and then a combination VX-809 and VX-770 or a placebo for 7 more days. The 
drugs were well tolerated, though about half of patients did report some adverse respiratory 
events, none of which were deemed serious. Furthermore, the most effective combination 
regiment showed significant total reductions in the sweat Cl- levels of 13 mmol/L from a 
baseline of ~100 mmol/L. The 14 days of solely VX-809 reduced sweat Cl- by 4 mmol/L. 
This is strong evidence that, first, VX-809 is able to direct CFTR to its operational location 
and, second, that VX-770 is able to increase the function of this most common mutated form 
of CFTR once it has been moved to that location. The final part of this study will begin at the 
end of 2011 (Pollack, 2011; and http://investors.vrtx.com/releasedetail.cfm?releaseid= 
583683). 
Ataluren (formerly known as PTC124®) is a protein restoration therapy that helps produce 
working copies from mutated forms of CFTR that harbor nonsense mutations 
(nmCF). Pioneered by PTC Therapeutics, Ataluren® is a small molecule compound that has 
shown clinical promise through phase 2 trials in the alleviation of several genetic disorders 
caused by nonsense mutations, including nmCF. Exclusively targeting nonsense 
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mutations, ataluren® overrides the premature stop codons symptomatic of these mutations 
to allow for the completion of the desired protein. In the case of nmCF, a small (19 
participant) phase 2 trial showed an ability to produce viable, working copies of CFTR via 
this “ribosomal read through” mechanism. The study showed significant improvements in 
total Cl- channel activity, measured by nasal transepithelial potential difference, which 
increased over time and led to improved pulmonary function and coughing. Ataluren was 
able to do this without interfering with other properly functioning stop codons, allowing the 
CFTR protein to be translated as initially designed and making the compound safe to 
administer. All trials of the compound have shown it to be well tolerated in humans with 
side effects mild and sparse to date. Ataluren®is currently in a 48 week CF phase 3 trial 
seeking statistically significant increased lung function, measured by FEV1 as its primary 
endpoint with safety and drug activity as secondary endpoints. Ataluren has orphan status 
from the FDA and European Commission as well as Subpart E for expedited development 
from the FDA. The phase 3 trial data will become available in the first half of 2012 
(Wilschanski et al., 2011; and http://www.ptcbio.com/3.1.1_genetic_disorders.aspx). 
3. Channel replacement therapy  
As indicated above, there are numerous approaches to treating this channelopathy. 
Combinations of these treatment modalities have increased the lifespan of those afflicted from 
4, to now greater than 35 years of age. Perhaps the most significant of these therapies has been 
the use of pancreatic enzyme replacements, anti-inflammatories and powerful antibiotics. 
While restoration of CFTR activity has been an ultimate goal through CFTR rescue and in 
particular gene therapy, these therapeutic approaches have helped only limited numbers of 
patients. We have advocated another approach: peptide-based channel replacement therapy. Under 
this scenario a channel-forming peptide is applied to the apical surface of CF airway tissues to 
promote anion secretion and surface hydration. Gene therapy, to date, has involved the 
delivery of a CFTR-encoding DNA segment encased in a viral capsid to the affected epithelial 
tissues. There are serious problems with the gene therapy delivery vectors, transformation 
efficiency and CFTR production and delivery. Also airway epithelial cells have limited half-
lives and the airway would need to undergo gene therapy on a regular basis to maintain 
expression. The new approach described here is much simpler (administered at home) and 
places the therapeutic directly on the target membrane (Fig. 1). Our efforts have been focused 
on developing a membrane-active peptide that can be delivered efficiently, assemble into a Cl- 
selective pore, trigger fluid secretion and elicit no detectable immune or inflammatory 
responses. The remainder of this chapter traces the development of this treatment modality. 
While many of the desired properties have been incorporated into this therapy some hurdles 
remain. These will be discussed later in the chapter.  
Chloride Channels Ion channels are usually multi-subunit protein molecules that have 
gated water-lined pores and an ion selectivity filter. Channels are individually gated by a 
variety of signals including ligands, non-covalent and covalent modifications, voltage, 
and/or mechanical stimuli. In most biological fluids, the most relevant physiological cations 
and anions are Na+, K+, and Ca2+; and Cl-, and HCO3-, respectively. An extensive literature is 
available to clearly document the high selectivity of naturally occurring cation channels in 
both excitable and non-excitable tissues (e.g., Kv, Nav, ENaC, Cav, etc.). Three major classes 
of Cl- channels have been cloned and studied. These include 1) the ligand gated channels 
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typified by inhibitory post-synaptic glycine, glutamate and GABA receptors; 2) CFTR, 
which is an ABC transporter family member exhibiting complex nucleotide-dependent 
gating; and 3) ClC channels, which appear to be ubiquitous and are both voltage and 
metabolically gated. Ion channel classes display significant structural differences in the 
conductive pathway.  
 
Fig. 1. The channel-forming peptide is delivered as an aerosol to the apical surface of CF 
airway cells. Upon binding to the surface it assembles to form an anion selective pathway to 
raise fluid secretion into the airway lumen thus rehydrating the airway surface fluid layer to 
allow proper cilia mediated airway clearance. 
Class 1, the cys-loop ligand-gated ion channel superfamily of neurotransmitter receptors, 
includes the anion-selective inhibitory post-synaptic glycine (GlyR) and aminobutyric 
acid type A (GABAAR) receptors, as well as cation selective nicotinic acetylcholine 
(nAChR), and 5-hydroxytryptamine type 3 (5-HT3R) receptors (Jensen et al., 2005; Sine and 
Engel, 2006) and the invertebrate post-synaptic glutamate receptor (Sunesen et al., 2006). 
These related structures all have a simple central pore defined by the parallel association of 
the second TM or ‘M2’ segments contributed by each of the five assembled subunits. 
Structural features common across members of this superfamily include the presence of 
heteropentameric bundles of subunits that are each composed of four hydrophobic TM 
segments, M1-M4, along with various sizes of intracellular and extracellular domains. Each 
M2 contributes a pore lining helix to form the channel. Unwin and co-workers (Unwin, 2003; 
Miyazawa et al., 2003; Unwin, 2005) published a 4 Å density map of the nAChR from 
Torpedo marmorata. The pentameric pore forms an hourglass-shaped pathway with the 
narrowest part at the middle of the lipid bilayer. The cation-conducting pathway, which is 
40 Å long and extends beyond the lipid bilayer, is formed by parallel helices that are 
aligned, in registry, such that the same residues in different helices form rings that define 
discrete microenvironments. S266, E262, T244, E241, S248, and S252 form polar rings and 
hydrophobic residues V255 and L251 form the narrowest portion of the pore. It is important 
to note that in this barrel and stave type pore, amino acids possessing R-groups with a full 
charge are present. These negatively charged R groups are located as sites where the 
hourglass geometry is more open. McCammon and co-workers (Ivanov et al., 2007) modeled 
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the 1-GlyR pore by threading the GlyR M2 helical segments onto the Unwin structure. 
Then, using molecular dynamics, they simulated the water density profile and Cl- 
translocation. A number of relevant conclusions were presented: the GlyR M2 pore is fully 
hydrated indicating that permeating Cl- is fully hydrated as well, no hydrophobic barrier 
was observed that would help in dehydrating the anion, and that the pore at its narrowest 
had a radius of 2.5 Å. These observations are in agreement with data that we have observed 
with our anion selective pores, which will be presented later. The McCammon group did 
not take into account any contribution of the M1-M2 loop toward anion selectivity. This 
extracellular loop, through mutational analyses, has been implicated in selectivity by several 
groups (Gunthorpe and Lummis, 2001; Jensen et al., 2005).  
Hilf and Dutzler (2008) published the first x-ray structure of a bacterial cys-loop channel at 
3.3 Å resolution in a presumed “closed-state”. This channel protein shares 16% sequence 
identity with the Torpedo nAChR protein. It is strictly a cation channel although there is 
little selectivity between Na+, K+, and Ca2+. It differs significantly from the mammalian cys-
loop channels in that no helical cytoplasmic domain is present. The authors were unable to 
identify any ion binding sites within the pore itself. This structure is of great significance 
since it provides key parameters such as the handedness of the helical bundle (left) and the 
tilt angle of the helices. The TM pore-forming helix is 25 residues in length with the pore 
lined by residues S226, E229, T233, T236, T240, A243, Y247 and I251. This structure provides 
key spatial coordinates for our modeling studies. 
GlyR 1-subunits alone have been shown to form homopentameric channels, when 
expressed in Xenopus oocytes, with properties similar to the parent channels (Schmeiden et 
al., 1989). The ability of this channel to function as a homo-pentameric array made it an 
attractive candidate for probing ion selectivity and permeation.  
Class 2 is represented by CFTR, the only channel member of the ABC transporter 
superfamily, which has 12 TM segments divided between two different halves each 
containing a nucleotide binding domain and linked by a regulatory domain (Riordan, 2008; 
Zhang et al., 2011). In a collaborative study with M. Montal, we identified four segments 
(M2, M6, M10, and M12) that assembled in synthetic bilayers to form a Cl- conducting pore 
(Montal, et al., 1994). Since that time other TM segments (M1, M3, M5 and M11) have been 
implicated in participating in pore assembly (Zhang et al., 2000; Linsdell, 2006). Others have 
suggested that the active channel is composed of a homo-dimer (Zerhusen et al., 1999). The 
selectivity filter is believed to reside in the M6 segment (Zhou et al., 2002). Mutational 
studies in M6 support this assignment (Beck et al., 2008; Alexander et al., 2009). Clearly, this 
channel structure is more complex than that observed for the GlyR in that the CFTR pore 
requires the assembly of multiple non-identical TM segments. 
Dawson and co-workers (Mansoura et al., 1998; Dawson et al., 1999; Smith et al., 2001; Liu et 
al., 2001) examined the selectivity properties of the CFTR channel, and proposed that 
reducing the dielectric of the pore is enough to cause anion selectivity. They prefaced their 
remarks by saying that the CFTR channel is probably a more primitive channel than the 
Class 1 channel types. CFTR exhibits lyotropic anion selectivity such that anions that are 
more readily dehydrated than Cl- are preferentially selected and show higher permeability 
rates. Their model predicts that larger anions, like SCN-, although they experience weaker 
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interactions (relative to Cl-) with water and the channel, are more permeant than Cl- (but 
with a smaller conductance). They appear to have a smaller net energy cost entering the 
channel relative to that of Cl-. That is, the reduced energy of hydration allows the net 
transfer energy (the well depth) to be more negative. The net positive charge of the pore 
lining residues also contributes to selectivity. 
Class 3 is the ClC channel family, which includes ClC-0, through ClC-7 in vertebrate species. 
This is the only family for which detailed structural assignments have been generated. 
Several bacterial ClC channels have been crystallized and analyzed with regard to the pore 
structure and the Cl- selectivity filter (Dutzler, et al., 2002; Dutzler et al., 2003). The active 
protein is a homo-dimer assembled from subunits that contain two identical anti-parallel 
domains. Each subunit contributes one channel to make a double-barreled channel 
structure. Each pore is made up of numerous anti-parallel helices of various lengths and 
contains two gating regions and a Cl- binding site. More recent crystallographic and 
mutational data suggest that there are three anion-binding sites within the open state of 
each pore in the highly conserved ClC family of channels and transporters (Lobet and 
Dutzler, 2006). The proposed central selectivity filter is composed, in part, using amide 
nitrogens from three different helices (N, F and D) pointing toward the anion-binding site. 
These amides are more positively charged because of the helix dipoles. The site also contains 
S107 and T445 (Corry and Chung, 2006). The amides and hydroxyls of these atoms are 
oriented such that they could form hydrogen bonds with Cl-. The serine side chain appears 
to be activated since the serine hydroxyl oxygen is also hydrogen bound to the amide 
nitrogen of I109. The anion never appears to interact with full positive charge from residues 
such as lysine or arginine. More recently three other residues have been implicated in 
selectivity through mutational studies K149, G352, and H401 in ClC-0 (Zhang et al., 2006). 
This class of channels is structurally distinct from the class 1 ligand-gated channels that 
contain a single pentameric array of parallel M2 helices of identical length. Despite these 
significant differences, the central ClC Cl- selectivity filter offers insight into the types of 
binding interactions that are utilized by Cl- selective channels. 
4. M2GlyR studies 
Early studies regarding first generation M2GlyR sequences When it became apparent that 
CFTR was a Cl- selective channel, finding and inserting an alternative Cl- conductive 
pathway into airway epithelia as a potential treatment modality became a realizable goal. 
Having already observed Cl- selectivity in synthetic phospholipid bilayers (Reddy et al., 
1993) with the M2 segment from the glycine receptor as both the free peptide (M2GlyR) and 
as a four-helix bundle (T4-M2GlyR) built with a template strategy (Mutter et al., 1989; 
Iwamoto et al., 1994), this sequence was an obvious choice to begin studying its effects on 
epithelial monolayers. Due to the complexity of synthesizing and purifying the template 
sequence, the studies focused on the more tractable monomeric form.  
The initial ion permeation studies in epithelial monolayers were conducted with the sequence 
PARVGLGITTVLTMTTQSSGSRA, corresponding to amino acids 250-272 in the glycine 
receptor protein, using confluent Madin-Darby canine kidney (MDCK) monolayers. When 
suspended at 100 µM in water containing 1% DMSO, the peptide caused a 1 μAcm-1 increase 
in short circuit current (Isc), an extremely sensitive indicator of net ion flux. The increase in ISC 
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occurred slowly with the net change being observed 30 minutes after peptide addition and this 
increase was observed only in 24 of 37 monolayers tested, suggesting inconsistencies in 
delivering the sequence to the membrane and then having it insert properly. In addition to the 
poor efficiency value, other drawbacks included limited solubility of the sequence and the 
inability to control the orientation of the inserted peptide in the bilayer.  
To decrease these deficiencies, the M2GlyR sequence was modified systematically by adding 
up to six lysyl or diaminopropionic acid (DAP) residues to either the C- or N-terminus 
(Tomich et al., 1998). This study examined a number of physical, pharmacological and 
physiological characteristics of the adducted sequences. Increasing the positive charge at 
either terminus increased solubility dramatically and also directed the orientation of the 
peptide within the bilayer. The effect was more dramatic for the C-terminus additions (Fig. 
2) with 5 lysines giving a peptide that showed solubility at saturation, in Ringer solution, of 
56.1 mM. Placing four lysines at either the C- or N-terminus appeared to be optimal in that 
these modified sequences yielded larger ISC values, greater aqueous solubility and exhibited 
nearly 100 percent efficiency in generating measurable changes in ISC. The resulting ISC was 
sensitive to bumetanide, a diuretic that blocks the activity of the Na+/K+/2Cl- cotransporter 
that is responsible for anion loading at the basolateral membrane, and to a non-selective Cl- 
channel blocker, DPC. The aqueous solubility increased from 1.4 mM for the unmodified 
sequence to 27.5 and 13.4 mM for the CK4- and NK4-M2GlyR sequences, respectively. ISC for 
CK4- and NK4-M2GlyR were larger by 2.7- and 1.2-fold, respectively.  
 
Fig. 2. Solubility as a function of net charge by the addition of lysines to either the C- or N-
terminus of M2GlyR 
Given the fact that adding lysines to either end improved solubility and showed increased 
magnitudes of net ion transport, studies were initiated to more fully describe the effects of 
CK4-M2GlyR on MDCK cell monolayers primarily because placing lysines at the C-terminus 
yielded a pore that had an orientation, relative to the cell membrane, that was identical to 
the native GlyR channel. Additionally, the presence of the C-terminal lysines would be 
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expected to stabilize the helix dipole. The helix dipole is important in the packing of 
adjacent helices such as those found in the helical bundle formed by the supramolecular 
assembly of the M2 peptides. 
CK4-M2GlyR significantly increased ISC, hyperpolarized transepithelial potential difference, 
and induced fluid secretion. In 28 monolayers, CK4-M2GlyR (100 µM) significantly 
increased ISC from 0.8 ± 0.1 to 3.3 ± 0.4 μAcm-2 and hyperpolarized transepithelial voltage 
(Vte) from 1.5 ± 0.4 to 3.5 ± 0.6 mV (apical bath negative). Transepithelial electrical resistance 
(Rte; a composite indicator of the transcellular and paracellular permeation pathways) 
decreased from 1,399 ± 341 to 1,013 ± 171 Ω cm2. In other experiments the increase in ISC was 
inhibited by bumetanide (100 µM) and by some Cl- channel inhibitors. The effectiveness of 
the channel blockers followed the sequence niflumic acid ≥ 5-nitro-2- (3-
phenylpropylamino) benzoate (NPPB) > diphenylamine-2-carboxylate (DPC) > 
glibenclamide. The effect of the peptide was not inhibited by 4,4’- diisothiocyanostilbene-2, 
2’-disulfonic acid (DIDS). Removing Cl- from the bathing solutions also abrogated the effect 
of the peptide. The Cl- efflux pathway induced by CK4-M2GlyR differs from the native 
adenosine 3’, 5’-cyclic monophosphate (cAMP)-mediated pathway that can be activated by 
adrenergic agonists and by forskolin. First, intracellular cAMP levels were unaffected and 
second, the concentration of DPC required to inhibit the effect of the peptide was much 
lower than that needed to block the forskolin response (100 μM vs. 3 mM). These results 
support the hypothesis that the synthetic peptide, CK4-M2GlyR, can form Cl--selective 
channels in the apical membrane of secretory epithelial cells and can induce sustained 
transepithelial Cl- secretion that can drive fluid secretion. ISC remained relatively constant 
for the first 2 h after the addition of the peptide. After 3 h, the CK4-M2GlyR-stimulated 
current was 90% of the current recorded at 60 min and decreased to 55% after 4 h. In 
washout experiments (n = 3), ISC was measured after removing CK4-M2GlyR from the bath. 
One hour after removal of the peptide, 39% of the CK4-M2GlyR-induced current remained, 
and, after 2 h, there was no persisting effect of the peptide. 
In a separate series of experiments (Wallace et al., 2000), transport of Cl- through the 
CK4-M2GlyR conductive pathway was modulated by basolateral K+ efflux through Ca2+-
dependent K+ channels. Application of CK4-M2GlyR to the apical surface of T84 cell 
monolayers (derived from human colon) generated a sustained increase in ISC and 
caused net fluid secretion. The current was reduced by clotrimazole, an inhibitor of SK 
and IK channels, and by charybdotoxin, a more selective and potent inhibitor of the 
KCNN4 gene product, KCa3.1, a Ca2+-dependent K+ channel. Direct activation of these 
channels with 1-ethyl-2-benzimidazolinone (1-EBIO) greatly amplified the Cl- secretory 
current induced by CK4-M2GlyR. The effect of the combination of CK4-M2GlyR and 1-
EBIO on ISC was significantly greater than the sum of the individual effects of the two 
compounds and was independent of cAMP. Treatment with 1-EBIO also increased the 
magnitude of fluid secretion induced by the peptide. The cooperative action of CK4-
M2GlyR and 1-EBIO on ISC was attenuated by Cl- transport inhibitors, by removing Cl- 
from the bathing solution, and by basolateral treatment with K+ channel blockers. These 
results indicate that apical membrane insertion of Cl- channel-forming peptides such as 
CK4-M2GlyR and direct activation of basolateral K+ channels with benzimidazolones 
may coordinate the apical Cl- conductance and the basolateral K+ conductance, thereby 
providing a pharmacological approach to modulate Cl- and fluid secretion by human 
epithelia deficient in CFTR. 
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Changes in the electrical properties of epithelial monolayers exposed to both 1-EBIO and 
CK4-M2GlyR were observed. Basolateral addition of 1-EBIO (600 μM) induced a small 
increase in ISC and doubled Vte with only a nominal decrease in Rte. Apical exposure of the 1-
EBIO-treated monolayers to CK4-M2GlyR (100 µM) caused an eight-fold increase in ISC from 
2.1 ± 0.2 to 16.5 ± 0.9 μAcm-2, hyperpolarized Vte hyperpolarized by 7.3±0.5 mV and reduced 
Rte by 1.53±0.33 KΩcm2. In two experiments, the response to 1-EBIO and CK4-M2GlyR was 
monitored for 5 h. ISC remained relatively constant during the first 60 min; however, ISC had 
decreased to 73% of this current at 2 h, 53% at 3 h, 41% at 4 h and 29% of the current at 5 h. 
In washout experiments (n=2), the current generated by the additions of 1-EBIO and CK4-
M2GlyR was monitored for a set period of time, then CK4-M2GlyR was washed out of the 
chamber. The removal of CK4-M2GlyR from the medium decreased ISC by 39%, whereas the 
subsequent removal of 1-EBIO decreased ISC to the control level. 
The addition of 1-EBIO increases the secretion of fluid induced by the apical application of 
CK4-M2GlyR to T84 cell monolayers. T84 cell monolayers were grown in four groups of 10 
monolayers, to test for the effects on the rate of transcellular fluid transport. Group I was 
incubated for 12 h in control medium, group II was exposed apically to CK4-M2GlyR (500 µM), 
group III was exposed to 1-EBIO (300 μM) and group IV was exposed to both CK4-M2GlyR 
and 1-EBIO. Monolayers incubated in control medium secreted fluid at a rate of 130 ± 40 nLh-
1cm-2, a value that was not significantly different from monolayers exposed to 1-EBIO (180 ± 30 
nLh-1cm-2). Monolayers exposed to just CK4-M2GlyR exhibited a significantly greater rate of 
fluid secretion, 250 ± 20 nLh-1cm-2 and a combination of CK4-M2GlyR and 1-EBIO increased 
the rate of fluid secretion further to 330 ± 20 nLh-1cm-2. These results demonstrated that anion 
secretion induced by the apical membrane insertion of CK4-M2GlyR drives the secretion of 
fluid and that the direct activation of basolateral K+ channels by 1-EBIO potentiates this effect 
on the rate of secretion. 
In other experiments, it was determined that the increase in Cl- and fluid secretion induced 
by combining CK4-M2GlyR and 1-EBIO was independent of intracellular cAMP levels since 
the addition of the two compounds did not significantly affect cAMP content. This implies 
that CK4-M2GlyR and 1-EBIO had minimal effect on CFTR Cl- conductance or other cAMP-
dependent processes. Therefore, we propose that the major action of 1-EBIO is to activate 
the Ca2+-dependent K+ channels and that the increase in the Cl- secretory current is due to 
increasing the electrochemical driving force for Cl- efflux through synthetic Cl- channels 
generated by the membrane insertion of CK4-M2GlyR. In summary, we have demonstrated 
that the synthetic Cl- channel-forming peptide, CK4-M2GlyR, induces Cl- and fluid secretion 
by T84 cells, which are derived from human intestine. Activators and inhibitors of a 
basolateral Ca2+-dependent K+ conductance modulated the magnitude of this response. We 
propose that the combination of the novel synthetic Cl- channel-forming peptide, CK4-
M2GlyR, and agents like 1-EBIO may have pharmacological benefits for inducing and 
modulating transepithelial Cl- and fluid secretion independent of the cAMP-dependent Cl- 
secretion that is impaired in CF. 
In a subsequent study we examined whether CK4-M2GlyR could exert effects on whole cell 
Cl- conductance in isolated epithelial cells, and if the observed effects were the result of 
formation of a novel Cl- conductance pathway, modulation of endogenous Cl- channel 
activity, or a combination of these effects. The outcomes indicated that extracellular 
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application of CK4-M2GlyR to isolated MDCK, T84, and IB3-1 cells resulted in increased 
permeability of the cells to Cl-. The experimental evidence suggested a direct mechanism of 
action. Studies looking at the effects of the oligo-lysine portion of the sequence suggested 
that a poly-lysine modified K4-helical peptide was not sufficient to activate endogenous 
CFTR through an electrostatic mechanism. 
The ability of CK4-M2GlyR to induce a time- and voltage-independent current in the IB3-1 
cell line, which lacks functional CFTR, suggested that CK4-M2GlyR does not increase Cl- 
current by activating CFTR. Furthermore, the pharmacological profile of the induced 
current supports this conclusion. Specifically, the CK4-M2GlyR-induced currents do not 
share biophysical characteristics of the hyperpolarization activated current associated with 
ClC-2 as determined with and without antisense ClC-2 cDNA, the swelling-activated 
current associated with Volume-Sensitive Organic Osmolyte/Anion Channels (VSOAC), 
with and without tamoxifen, and the Ca2+-dependent Cl- current activated by CaM Kinase 
II, with and without KN-62. Together, these results support the premise that the M2GlyR 
peptides increase ISC across epithelial monolayers by forming a novel permeation pathway 
for Cl- rather than by activation of endogenous Cl- conductances. 
In some of the most compelling work done to test the validity of the peptide-based channel 
replacement therapy, nasal potential difference (PD) studies were performed at the Gregory 
Fleming James Cystic Fibrosis Center at the University of Alabama, Birmingham, under the 
direction of Dr. Eric Sorscher. More than 40 mice were tested for effects of either CK4-
M2GlyR or NK4-M2GlyR. A standardized protocol that employs transitions to amiloride, Cl-
-free medium, and exposure to adrenergic stimuli was employed. The ΔF508 homozygous 
transgenic mouse nasal epithelia exhibit ion transport defects identical to those in CF human 
airways and, thus, are an excellent model to test for potential therapeutic effects. Ion 
transport was assessed by repeated nasal PD measurements in both transgenic and wild-
type mice (Brady et al., 2001). Key data from a double-blind study employing both CK4-
M2GlyR and NK4-M2GlyR are summarized in Fig. 3. As expected, isoproterenol, in a Cl--
free medium containing amiloride, caused a positive shift in nasal PD of CF mice (CF 
control) while causing a negative shift in the nasal PD of wild-type (WT) littermates. 
Importantly, following exposure of CF nasal epithelia to either CK4-M2GlyR or NK4-
M2GlyR (500 µM) the effect of isoproterenol more closely resembled the effect in the WT 
animals than in the CF animals that received no peptide or were exposed to either of two 
control peptides that were expected to have no effect. Control #1 was too short to span the 
bilayer of a cell membrane and Control #2 (NK4-Sc) has its transmembrane segment 
randomized, although computer modeling was employed to maximize helical propensities 
while minimizing the amphipathic character of the helix. Sustained Cl- conductance was 
observed for up to 6 h after a single application of peptide in solution. While this outcome is 
very encouraging, this type of treatment would have to be administered one or more times 
per day for optimal clinical results. 
Concurrent exposure to 1-EBIO changed the direction for the development of M2GlyR 
channel-forming peptides. Initially, most studies were performed using CK4-M2GlyR. 
However, CK4-M2GlyR and NK4-M2GlyR behaved differently in the presence of the K+-
channel opener. N-terminal modification of a channel-forming peptide increases capacity for 
epithelial anion secretion. In Ussing chamber experiments, apical exposure of MDCK and 
T84 cell monolayers to NK4-M2GlyR (250 µM) increased ISC by 7.7 ± 1.7 and 10.6 ± 0.9 μAcm-
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2, respectively (Broughman et al., 2001). These values are significantly greater than those 
previously reported for the same peptide modified by adding the lysines at the C- terminus 
(Wallace et al., 1997). NK4-M2GlyR caused a concentration-dependent increase in ISC (k1/2 = 
190 µM) that was potentiated two- to threefold by 1-EBIO (300 μM). NK4-M2GlyR-mediated 
increases in ISC were insensitive to changes in apical cation species. Pharmacological 
inhibitors of endogenous Cl- conductances (glibenclamide, DPC, NPPB, DIDS, and niflumic 
acid) had little effect on NK4-M2GlyR-mediated ISC. Whole cell membrane patch-voltage 
clamp studies revealed an NK4-M2GlyR-induced anion conductance that exhibited modest 
outward rectification and modest time- and voltage-dependent activation. Planar lipid 
bilayer studies indicated that NK4-M2GlyR forms a 50-pS anion conductance with a k1/2 for 
Cl- of 290 mEq. NK4-M2GlyR was similar to the previously characterized analog, CK4-
M2GlyR, in that both sequences elicited increases in the anion-selective current in lipid 
bilayers, whole cell membrane patches, and epithelial monolayers. When employed at 
similar concentrations, NK4-M2GlyR provided for greater anion secretion across epithelial 
cell monolayers than any related channel-forming peptide tested to this point. Effects for 
NK4-M2GlyR were observed with as little as 25–30 μM, and maximal effects were observed 
with about 500 μM (Table 1 and Fig. 4; Broughman et al., 2002a).  
 
Fig. 3. Isoproterenol-induced change in nasal PD of ΔF508 homozygous mice and wild-type 
littermates in the absence or presence of indicated peptides. 





1. PARVGLGITTVLTMTTQSSGSRA M2GlyR 2304.7 1.4 N/A N/A N/A 
2. PARVGLGITTVLTMTTQSSGSRAKKKK CK4-M2GlyR 2817.4 27.5 
2.7 ± 
0.9 102.5 >500 
3. KKKKPARVGLGITTVLTMTTQSSGSRA NK4-M2GlyR 2817.4 13.4 
1.52 ± 
0.55




Table 1. Characterization of M2GlyR peptides with C- and N-terminal oligo-lysine adducts. 
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Fig. 4. The dependence of ISC of MDCK monolayers on NK4-M2GlyR and CK4-M2GlyR 
concentration in the presence of 1-EBIO. Solid lines represent the best fit of a modified Hill 
equation to the data sets. 
The resulting parameters for NK4-M2GlyR (Imax = 25.2 ± 10.4 μAcm-2, k1/2 = 319 ± 192 μM, n 
(Hill coefficient) = 1.52 ± 0.55) are similar to those reported above , Imax = 24.3 ± 0.5 μAcm-2, 
k1/2 = 208 ± 6 μM, and n = 2.6 ± 0.1). This degree of cooperativity suggests that a multi-step 
process is required to form functional channel assemblies. Whether the cooperative step 
involves membrane partitioning, assembly of the helical bundles into structures, or a 
combination of these necessary steps for channel formation is not known. The concentration 
dependence of CK4-M2GlyR is right-shifted compared to that of NK4-M2GlyR, with the 
response at the greatest concentration tested (500 μM) showing no indication of saturation. 
The experimental data for CK4-M2GlyR, when fitted by the modified Hill equation, resulted 
in a substantially greater value for Imax than that observed for a variety of agonists and pore-
forming peptides (25–30 μA cm-2). When employed at similar concentrations, NK4-M2GlyR 
provides for greater anion secretion across epithelial cell monolayers than any related 
channel-forming peptide tested thus far. These results indicate that NK4-M2GlyR forms an 
anion-selective channel in epithelial monolayers and again showed its therapeutic potential 
for the treatment of hyposecretory disorders such as CF.  
One of the early applications of NK4-M2GlyR included a study looking at the effect of 
exogenously applied peptide to the surface of immortalized human tracheal epithelial cells 
from a homozygous ΔF508 CFTR CF patient (Yankaskas et al., 1993). CF is characterized by 
defective epithelial Cl- transport with damage to the lungs occurring, in part, via chronic 
inflammation and oxidative stress. Glutathione, a major antioxidant in the airway lining 
fluid, is decreased in CF airway due to reduced glutathione efflux (Gao et al., 1999). This 
observation prompted a study to examine the question of whether exposure to channel-
forming peptides would also restore glutathione secretion (Gao et al., 2001). Addition of the 
Cl- channel-forming NK4-M2GlyR (500 μM) and a K+ channel activator (chlorzoxazone, 500 
μM) increased Cl- secretion, measured as bumetanide-sensitive ISC, and/or glutathione 
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efflux, measured by high-performance liquid chromatography, in a human CF airway 
epithelial cell line (CFT1). Addition of the peptide alone increased glutathione secretion (181 
± 8% of the control value), whereas chlorzoxazone alone did not significantly affect 
glutathione efflux; however, chlorzoxazone potentiated the effect of the NK4-M2GlyR on 
glutathione release (359 ± 16% of the control value). CK4-M2GlyR has decreased efficacy 
compared with NK4-M2GlyR in both ISC and GSH efflux assays. The addition of 1-EBIO also 
amplified the effect of NK4-M2GlyR (500 µM) on GSH efflux (286 ± 1 % of control values). 
These studies demonstrated that glutathione efflux can be modulated by channel-forming 
peptides and is likely associated with Cl- secretion, not necessarily with CFTR per se, and 
the defect of glutathione efflux in CF can be overcome pharmacologically. 
Both orientations of the M2GlyR helix within the membrane form anion-selective pores. 
However, differences in solubility, solution associations and channel-forming activity for 
the oligo-lysyl adducted forms were observed. While deciding on which of the oligo-lysine 
adducted M2GlyR peptides to develop further, we began a study utilizing chemical cross-
linking, NMR and molecular modeling to determine how the positioning of the lysyl 
residues affected the channel properties and structural characteristics. These sequences are 
amphipaths with distinct clusters of hydrophobic and hydrophilic residues. In aqueous 
solution, hydrophobic patches associate and hydrophilic ones are solvent exposed. This 
property generally leads to aggregation through a concentration dependent process. This 
model predicts that multiple higher molecular weight assemblies, which do not readily 
interact with membranes, would be formed (Fig. 5). Evidence indicating aggregate 
formation is discussed below. A preferred outcome, however, would be to have a peptide 
that remained predominantly monomeric in solution while retaining its membrane binding 
and insertion activities. The actual sequence of insertion and assembly events leading to a 
functional channel are still unresolved. We do know that much of the process is slowly 
reversible based on perfusion washout experiments (indicated by the double ended arrows). 
Two possible routes are shown. One (right) has the peptide inserting and folding as a single 
step followed by assembly. The second (left) has peptide folding occurring at the surface 
followed by assembly as a prerequisite for insertion. A mixture of the two pathways could 
also be possible. Optimization of the channel-forming structure included modifications to 
reduce solution oligomerization and thereby increase the concentration of peptide that 
could insert and form active assemblies. CK4-M2GlyR and NK4-M2GlyR formed aggregates 
in aqueous solutions to differing degrees, as shown in Fig. 6. A cross-linking reagent was 
used to trap solution aggregates that were visualized using sodium dodecyl sulfate – 
polyacrylamine gel electrophoresis (SDS-PAGE) (Broughman et al., 2002b). Bis 
[Sulfosuccinimidyl] suberate (BS3), a water-soluble homo-bifunctional cross-linking reagent 
that reacts with free amino groups in the lysine adducts was employed. The cross-linking 
reactions were carried out in 10 mM 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid 
(HEPES) buffer, pH 6.5, at selected peptide concentrations in the presence of a 40-fold molar 
excess of cross-linking reagent. The results from a typical experiment are shown in Fig. 6. 
Lanes 5 and 9, show the electrophoretic mobility of non-cross-linked CK4-M2GlyR and NK4-
M2GlyR boiled in 10% SDS, respectively. Under these conditions both sequences are 
monomeric, indicating that the solution associations that are trapped with the cross-linking 
reagent (in the adjoining lanes) are dissociated in the presence of the anionic detergent. The 
cross-linked molecular weight profiles for the two sequences are strikingly different. CK4-
M2GlyR forms lower molecular weight associations with monomer through trimer being 
www.intechopen.com
 
Channel Replacement Therapy for Cystic Fibrosis 
 
309 
the most prevalent. NK4-M2GlyR forms many more associated forms, starting with 
monomer and going beyond 20-mers. Comparing the relative concentration of monomer to 
the higher species for each of the sequences, monomer is the most abundant species for CK4-
M2GlyR while in NK4-M2GlyR the monomer accounts for less than 50% of the captured 
species. This result was somewhat surprising since NK4-M2GlyR has considerably more 
activity per peptide concentration even though there is apparently a smaller percentage of 
monomer able to bind and insert into the membrane. 
 
Fig. 5. Solution and membrane inserted states for channel-forming peptides. 
 
Fig. 6. Silver-stained polyacrylamide gel of cross-linked NK4-M2GlyR and CK4-M2GlyR. 
Assuming that the energy barrier for the translocation of the four-lysyl residues across the 
hydrophobic membrane is prohibitive (Vogt et al., 2000), either orientation (NH2 or COOH 
terminal towards extracellular surface) can insert into the membrane and assemble into an 
anion-conducting pore. However, based on the observation that the concentration required 
to produce 50% of the maximum increase in ISC (k½) for NK4-M2GlyR is one-third less than 
that required for CK4-M2GlyR (319 μM vs. 553 μM, respectively), the efficiency of the 
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insertion or the assembly of these two peptides into channel-forming structures is not 
equivalent. Furthermore, the concentration-dependent effects of the peptides on ISC show a 
smaller Hill coefficient for NK4-M2GlyR than CK4-M2GlyR (n = 1.5 vs. 2.3, respectively). 
This suggests that one or more of the steps required for channel assembly (e.g., insertion, 
oligomerization) is/are more cooperative in the case of CK4-M2GlyR. Alternatively, as NK4-
M2GlyR is less soluble than CK4-M2GlyR in aqueous solution, the hydrophobic driving 
force for the insertion of NK4-M2GlyR into the membrane is greater. In either case, 
structural differences between the lysine-modified peptides result in altered channel-
forming activity. 
A series of one- and two-dimensional NMR experiments were performed on NK4- and CK4-
M2GlyR. TOCSY NMR spectra were recorded for each (Broughman et al., 2002b). Data 
presented in Fig. 7 show the fingerprint region (NH to C and side chain proton 
connectivity) for 500 MHz 1H 2D-experiments for both peptides recorded in water 
containing 30% deuterated trifluoroethanol (TFE) at 30°C (assignments are shown for the 
lysine residues). The extent of chemical-shift dispersion of the backbone proton resonances, 
particularly of the lysine residue amide protons (in spite of the oligomeric nature of the 
lysines in these sequences), suggest that such a spread of chemical shift can be induced only 
by secondary structure. However, in comparing the chemical shifts for the lysine residues in 
the two TOCSY spectra, it is clear that the environments for these basic amino acids in the 
two peptides are distinct. For the NH2-terminal lysine adducted peptide the dispersion 
range of the TOCSY chemical shifts for 3 of the 4 lysines was 8.55 to 8.1 ppm. The fourth 
lysine could not be assigned. In contrast, the COOH-terminal-adducted peptide had a 
dispersion range of chemical shifts that spanned 8.15–7.72 ppm. All four of the CK4-M2GlyR 
lysine resonances were assigned. Greater dispersion in the chemical shift pattern observed 
with NK4-M2GlyR indicates that these residues are more mobile and solvent exposed while 
the lysine residues adducted to the COOH-terminus are hydrogen bonded intramolcularly.  
 
Fig. 7. TOCSY NMR spectra (500 MHz) of NK4-M2GlyR and CK4-M2GlyR. 
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The NMR coordinates for CK4-M2GlyR and NK4-M2GlyR were modeled using a 
combination of energy based minimizations and molecular-dynamics simulations. The 
lysine residues of CK4-M2GlyR form a C-cap by extensive H-bonding interactions with the 
helix backbone, which remain fairly static throughout the molecular dynamics simulation 
period. The side chain -amino group of K24 of CK4-M2GlyR forms a capping structure that 
stabilizes the helix by forming H-bonds with the backbone carbonyl groups of S21, R22 and 
A23, fulfilling H-bonding interactions that are absent in the COOH terminal residues of an 
-helix. The -amino group of K25 of CK4-M2GlyR forms H-bonds with the backbone 
carbonyl groups of T16 and K-27 and the hydroxyl side chain of T16. The -amino groups of 
K26 and K27 of CK4-M2GlyR form hydrogen bonds to the backbone carbonyl of K25 and the 
side chain carbonyl of Q17, respectively. The side chain -amino groups of K1 and K4 of 
NK4-M2GlyR do not form H-bonds, as the lysyl residues’ side chains extend away from the 
helix backbone. There was very little motion of the helix backbone of CK4-M2GlyR during 
the simulation period. In contrast, the lysine residues of NK4-M2GlyR remained mostly 
extended away from the helix during the simulation, interacting minimally with the 
M2GlyR backbone. These differences in dynamics could affect the rates of assembly and 
pore geometries. Large differences are predicted for the dipoles of NK4-M2GlyR and CK4-
M2GlyR (Fig. 8 left and right structures, respectively). Note the similarities, both in 
magnitude and in orientation, between the dipoles of the unmodified M2GlyR sequence and 
NK4-M2GlyR. The dipole of CK4-M2GlyR is shifted by nearly 90 degrees and is less than 2% 
of the magnitude of the dipole for the parent compound. This perturbation of the dipole 
could play a role in the differences observed in peptide-peptide association and channel 
activity of the CK4-M2GlyR peptide. 
 
Fig. 8. The dipole moments of NK4-M2GlyR (left), M2GlyR (center) and CK4-M2GlyR (right) 
are shown as ribbon structures (magenta is helix and cyan is random coil) with the dipoles 
represented by green arrows. For this representation, the dipoles of NK4-M2GlyR and 
M2GlyR were scaled down by a factor of 20, while the dipole for CK4-M2GlyR was scaled 
up by a factor of 3. 
To identify the portion of the M2GlyR molecule that was promoting the solution assemblies of 
NK4-M2GlyR, channel activity and cross-linking experiments were performed on various 
truncated forms of CK4-M2GlyR and NK4-M2GlyR. The results (Figs. 9 and 10) suggested that 
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a nucleation site for self-association of the peptide is located near the COOH-terminus of the 
M2GlyR sequence since removal of five residues (SGSRA) from the C-terminus of NK4-
M2GlyR resulted in a reduction of higher molecular weight species. Importantly, there was 
little loss of ion transport activity. Removal of additional C-terminal residues led to a 
progressive decrease in ISC, although there was a slight reduction in apparent solubility to 11.1 
mM. Measurable activity was observed with even 11 residues removed from the C-terminus. 
In contrast, the nucleation site is likely masked by the oligo-lysine tail at the COOH-terminus, 
which prevents formation of higher order assemblies by CK4-M2GlyR and removal of residues 
from the N-terminus of CK4-M2GlyR had little effect on the various low molecular weight 
associations. However, these truncated forms exhibited substantially less ion transport 
activity. The truncated NK4 sequence, referred to as NK4-M2GlyR-p22, became the lead 
compound for further development. Removing the five residues greatly reduced the cost of 
synthesizing a purer peptide with fewer failed sequences. 
 
Fig. 9. Silver-stained Tricine polyacrylamide gel of cross-linking patterns for truncated CK4-
M2GlyR and NK4-M2GlyR treated with a 40-fold excess of crosslinking reagent.  
 
Fig. 10. ISC induced by the full length and truncated NK4-M2GlyR and CK4-M2GlyR 
peptides (500 μM) on MDCK epithelial monolayers. Symbols represent the mean and 
standard error of three to seven observations.  
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Results described thus far indicate that the native M2 sequence that forms the GlyR pore can 
be employed to form de novo anion selective channels in epithelial cell membranes. Further, 
the structure can be optimized to enhance aqueous solubility and to decrease solution 
aggregation, which increases effective bioavailable concentration. Lysyl-adduction at the 
amino terminus appeared to be preferred based upon outcomes with truncated peptides. An 
additional and exciting outcome of these truncation studies was that shorter peptides might 
be used to achieve the therapeutic goal, which provides for many potential benefits in 
design and delivery of this therapeutic modality. 
Studies on the second generation of NK4-M2GlyR-p22 sequences In the process of 
truncating the NK4-adducted M2GlyR sequence, a number of hydrophilic residues were 
eliminated as defined by the Wimley and White hydrophobicity scales developed for TM 
sequences (Wimley and White, 1996; Wimley and White, 1999; Wimley and White, 2000; 
Jayasinghe et al., 2001). The increase in hydrophobicity was reflected in reduced solubility 
for the deletion peptides. Among the residues removed was R22 in the C-terminus of the 
parent M2 sequence. It has been postulated, based on solution NMR studies in dodecyl 
phosphatidylcholine micelles, that the registry of the wild-type TM segment is defined by 
residues R3 and R22, thereby defining an 18-residue TM segment (Tang et al., 2002; 
Yushmanov et al., 2003). Arginine is often located at the water/lipid interface in TM 
segments (Vogt et al., 2000; Harzel and Bechinger, 2000; Mitaku et al., 2002). Without the C-
terminal R in the NK4-M2GlyR-p22 sequence, both ion selectivity and positioning, and 
registry of the TM segment within the acyl lipid core are potentially compromised. 
Therefore, a study was initiated to evaluate the effects on channel transport properties of 
reintroducing an R at positions near the new carboxyl-terminus. Arginine residues were 
introduced individually at positions 18 through 22 and in subsequent experiments double 
amino acid replacements were generated with aromatic amino acids placed at or near the C-
terminus along with R at positions 19-22. MDCK monolayers were used to assess peptide-
dependent ion transport.  
A series of five individual C-terminal R substitutions were made placing R at the following 
positions: M18R, T19R, T20R, Q21R and S22R (Shank et al., 2006). With the exception of 
M18R, the substituted peptides generally exhibited similar concentration dependent ISC 
profiles in MDCK monolayers (Table 2). Substitution of an R enhanced solubility by 50% or 
more, did not affect the Hill coefficient (n), showed similar half maximal activity (k1/2) values 
and had similar helical content as judged by circular dichroism recorded using 50 μM 
peptide in 10 mM sodium dodecyl sulfate (SDS). Cross-linking experiments using BS3 
revealed that all of these substituted sequences showed solution aggregation patterns 
similar to that seen for NK4-M2GlyR-p22 (e.g., see Fig. 9). 
Rather than rely simply on an R to define the lipid-water boundary at the truncated end of 
M2GlyR, a W was used to replace the C-terminal serine. A propensity for tryptophans 
residing at the aqueous/lipid interface also had been observed and tested by others (Braun 
and von Heijne, 1999; Mall et al., 2000; Demmers et al., 2001; de Planque et al., 2003; 
Granseth et al., 2005; van der Wel et al., 2007; Hong et al., 2007). Placing a W at the C-
terminus sets the registry of the TM segment that spans the bilayer. In the absence of an R or 
aromatic residue at or near the C-terminus, the peptide could rise up and down within the 
fluid bilayer thereby affecting the depth of peptide insertion into the membrane and tilt 
angle of the peptide. By limiting mobility, the degrees of freedom for the TM registry of the 
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peptide are reduced. During the assembly process this allows the annealing peptides to find 
their preferred interfacial contacts faster and at a lower concentration. Fig. 11 shows the 
concentration dependence on ISC for the full length and the truncated M2GlyR peptides 
when applied to the apical membrane of MDCK cells in the presence of 1-EBIO (Cook et al., 
2004). The solid lines represent the best fit of a modified Hill equation to each data set. In 
paired monolayers both NK4-M2GlyR-p27 and NK4-M2GlyR-p22 peptides (previously 
characterized in Broughman et al., 2002a) displayed similar concentration dependency 
curves and induced similar ISC at each concentration tested. Introduction of the W in NK4-
M2GlyR-p22 S22W yielded a curve with a reduced IMAX (13.0  1.0 μAcm-2) but more 
importantly a significantly reduced k1/2 (44 ± 6 μM) with a considerably greater Hill 
coefficient of 5.4 ± 2.9. The sum effect of changes in the three kinetic parameters (IMAX, k1/2, 
and Hill coefficient) is a substantial reduction in the peptide concentration required to yield 





Mr (Da) Sol.(mM) n 
IMAX 
(μA/cm2) k1/2 (μM) 
1. KKKKPARVGLGITTVLTMTTQS none 2358.9 11.1 
1.9 ±  
0.6 
23.7 ±  
5.6 
210 ±  
70 
2. KKKKPARVGLGITTVLTMTTQR S22R 2427.9 15.6 
2.7 ±  
0.9 
24.1 ±  
5.3 
290 ±  
60 
3. KKKKPARVGLGITTVLTMTTRS Q21R 2387.0 19.7 




390 ±  
220 
4. KKKKPARVGLGITTVLTMTRQS T20R 2414.0 18.7 




310 ±  
227 
5. KKKKPARVGLGITTVLTMRTQS T19R 2414.0 18.3 
0.7 ±  
0.6 




6. KKKKPARVGLGITTVLTRTTQS M18R 2383.9 23.3 
0.6 ±  
2.6 
3.0 ±  
4.0 
840 ±  
200 
Table 2. Characterization of M2GlyR-p22 derived peptides with C-terminal Arginines. 
We then assessed the solution associations of the selected NK4-M2GlyR peptides using a 
silver-stained gel following cross-linking reactions. In Fig. 12, lane 1 (consistent with 34:9-
11) contained a mobility standard to indicate relative molecular weights. Lanes 2 through 9 
contain the indicated peptides that were suspended in aqueous buffer in the absence and 
presence of a twenty-fold excess of BS3, as indicated The cross-linker revealed the presence 
of higher molecular weight homo-oligomers. Without the addition of cross-linker and after 
boiling the sample in SDS containing loading buffer, only monomer was observed. The W 
substituted sequence, however, appeared to be predominantly monomeric in solution under 
either experimental condition. These results indicated that NK4-M2GlyR-p22 S22W (150 μM) 
forms essentially no aggregates in aqueous solution and the entire suspended mass is 
capable of membrane interaction.  
It is unclear whether the left shift in k½ observed for the W containing peptide in Fig. 11 is 
due solely to an increase in concentration of the membrane active monomeric species or 
includes a contribution from the C-terminal W limiting the possible orientations of the 
peptide within the bilayer. The change in the Hill coefficient is likely due to the addition of 
the membrane anchor that facilitates the supramolecular assembly of the peptides into an 
active oligomeric pore. We speculated that the anchor reduces the degrees of freedom for 
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the TM segment making alignment more favorable during assembly. An alternative 
explanation could be that in the absence of the tryptophan there is both positive and 
negative cooperativity. Addition of the tryptophan eliminates the negative cooperativity 
and we see the level of positive cooperativity that might be expected for the assembly of a 
pentameric structure. The presence of the fluorescent tryptophan also provides both a 
convenient method for determining the concentration of the peptide solution and a sensitive 
tool for probing the environment surrounding the indole.  
 
Fig. 11. Concentration-dependence of ISC induced by NK4-M2GlyR derived peptides on 
MDCK epithelial monolayers. The NK4-M2GlyR derived peptides concentration dependent 
ISC curves are as follows: NK4-M2GlyR p27(◊), NK4-M2GlyR p22 WT () and NK4-M2GlyR 
p22 S22W (∆). 
 
Fig. 12. NK4-M2GlyR and derivative peptide solutions (150 μM) mixed without (-) and with 
(+) a 20-fold excess of BS3 cross-linker.  
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NMR structural and computer modeling studies were carried out on 40% deuterated TFE 
solutions of NK4-M2GlyR-p22 and NK4-M2GlyR-p22 S22W to determine how the 
substituted C-terminal W potentially influences solution associations of the peptide (Cook et 
al., 2004). A measurement of the NK4-M2GlyR-p22 (WT) peptide structure shows that the 
length of the entire TM segment is greater than 32 Å, more than enough to span the 
hydrophobic core of the membrane (Fig. 13, left structure). This structure is similar to the 
results shown in micelle studies done on the wild-type glycine receptor 1 subunit (Tang et 
al., 2002; Yushmanov et al., 2003). An identical segment of the peptide was determined to be 
helical when incorporated in SDS micelles. The rest of the peptide was unstructured and 
flexible, including the C-terminus. The outcomes indicated that the structured portion of the 
peptide is restricted to residues 8 to 22 regardless of the length of the peptide. The WT 
structure resembles other TM segments observed in the x-ray crystal structure of a ClC 
chloride channel. In that structure, the Cl- binding TM segments are made up of shorter 
helices that do not completely span the width of the membrane (Dutzler et al., 2002; Esrévez 
and Jentsch, 2002).  
 
Fig. 13. Calculated models of NK4-M2GlyR-p22 and NK4-M2GlyR-p22 S22W in TFE.  
The structured C-terminus of NK4-M2GlyR-p22 S22W is made up of a single-turn helix 
(residues 11 - 14), a stretched beta-like turn (residues 14 - 17), and then another two-turn 
helix (residues 15 - 21). The observed structure indicated a helical content of about 40%, 
which was in good agreement with CD data for the S22W containing 22-residue peptide. 
This backbone structure allows the peptide to loop or fold over into a closed structure (Fig. 
13). This fold sequesters the hydrophobic residues such that the acyl side chains have 
reduced solvent exposure. The structure likely has little relevance to a TM segment where 
the aliphatic side chains would be fully exposed and interacting with the lipid acyl chains in 
the membrane bilayer. Nonetheless, the C-terminal fold of NK4-M2GlyR-p22 S22W explains 
why the peptide remains in the monomeric form in solution, since the hydrophobic groups 
are less exposed and unable to associate with hydrophobic groups from other peptides. 
While TFE is not added to peptide stock solutions used for assessing channel activity, it is 
clear that this monomer-inducing fold is sampled with enough frequency that the higher 
molecular weight forms do not occur. Based on the CD spectra obtained using 10 mM SDS 
micelles, the peptide is able to adopt a more helical structure, much like the WT peptide. 
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NMR studies in SDS (Fig. 14) confirmed the CD results (Herrera et al., 2010). These atomic 
structures clearly show that both NK4-M2GlyR-p22 (WT) and NK4-M2GlyR-p22 S22W are 
linear and mostly helical from residues 6–20 in SDS micelles. The N-terminal lysines are 
largely unstructured and apparently exhibit substantial flexibility. These lysine residues are 
expected to be out of the micelle floating in the aqueous environment and/or interacting 
with the sulfate groups. The hydrophobic and hydrophilic side chains are segregated to 
different sides of the helix, as expected for channel forming TM segments. 
 
Fig. 14. Average structures of NK4-M2GlyR-p22 and NK4-M2GlyR-p22 S22W after MD 
refinement in an implicit membrane. Backbones are shown as a blue tube with licorice side 
chains. 
 WT S22W 
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NMR structures, along with a range of additional experimental data and theoretical 
considerations, were utilized to assemble the monomer structure into channels, including 
oligomerization state, pore-lining interface, helix packing distance, and tilt angle. In 
particular, experimental identification of the pore-lining residues greatly reduces 
uncertainty of the channel assembly and allows the construction of reliable initial structural 
models. All-atom molecular dynamics (MD) simulations in fully solvated 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC) bilayers were subsequently carried out to refine 
these structural models and to characterize and validate the structural and dynamical 
properties of the channels (Fig. 15). The results demonstrate that the channel structures as 
constructed are adequately stable within the simulation time frame (up to 20 ns) and remain 
sufficiently open for ion conductance. All initial structures relax to transiently stable 
structures within a few nanoseconds. Analysis of the relaxed structures of NK4-M2GlyR-p22 
WT and NK4-M2GlyR-p22 S22W reveal important differences in their structural and 
dynamical properties, providing a basis for understanding the differences in channel 
activities. Specifically, the structural characterization supports the initial postulation that the 
S22W substitution in NK4-M2GlyR-p22 helps to anchor the peptide in the membrane and 
reduces the flexibility of the whole assembly. The implied increased stability of the NK4-
M2GlyR-p22 S22W channel potentially explains the steeper short circuit current-
concentration slope measured experimentally. Furthermore, introduction of the C-terminal 
W appears to lead to global changes of the channel structure. The NK4-M2GlyR-p22 S22W 
channel maintains a smaller opening at the narrowest region and throughout the rest of the 
pore compared with the NK4-M2GlyR-p22 channel. The smaller size of NK4-M2GlyR-p22 
S22W could effectively reduce its ion throughput or conductance by a magnitude that is 
consistent with a nearly 50% reduction in measured IMAX. The ability to recapitulate these 
differences in key physiological properties observed experimentally is an important 
validation of the proposed structural models. 
 
Fig. 15. Snapshots of NK4-M2GlyR-p22 and NK4-M2GlyR-p22 S22W left-handed channels in 
a fully solvated POPC bilayer before and after the 20 ns production simulation. Both 
peptides have identical structures at t = 0.The protein is shown in purple cartoon and lipid 
molecules shown in the grey licorice with phosphorus atoms shown as orange spheres. 
Development of third generation NK4-M2GlyR-p22 derived sequences From a drug 
delivery perspective, adding the W at the C-terminus yields a compound that can be 
delivered from solution at a stable accurate concentration and at considerably lower 
dosages. Both having the peptide predominantly as the monomer and treating with lower 
dosages dramatically reduce the cost of the treatment. For the third generation sequences 
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substitutions were made based on increasing conductance and anion selectivity. In an 
attempt to enhance anion selectivity by reintroducing a charged residue at or near the C-
terminus of the W-substituted sequence, a series of doubly substituted peptides were 
prepared. Restoration of a positive charge near the C-terminus of the 22-residue peptide was 
first tested with regard to increasing throughput rates. A helical wheel projection of the 
M2GlyR-p22 helix revealed an even distribution of the polar residues. Not knowing where 
to optimally substitute an R, a series of M2GlyR peptides was prepared with R replacing one 
amino acid in each of the four C-terminal sequence positions.  
NK4-M2GlyR-p22 displayed concentration-response relationships similar to those observed 
with the 27 residue full-length CK4-M2GlyR and NK4-M2GlyR peptides. Table 3 presents 
the summarized ion transport kinetic constants associated with the fitted lines presented in 
Fig. 16. NK4-M2GlyR-p22 displayed a concentration-dependent response similar to that 
observed with the 27 residue full-length CK4-M2GlyR and NK4-M2GlyR peptides. NK4-
M2GlyR-p22 provided benchmark values for IMAX of 23.7  5.6 µAcm-2, k1/2 of 210 ± 70 M, 
and Hill coefficient of 1.9 ± 0.6. 
 
Fig. 16. Concentration-dependence of ISC induced by NK4-M2GlyR-p22 derived peptides 
with W and R amino acid substitutions on MDCK epithelial monolayers. Symbols represent 
the mean and standard error of 6 or greater observations for each concentration tested. Solid 
lines represent the best fit of a modified Hill equation to each data set. The NK4-M2GlyR 
derived peptides concentration dependent ISC curves are as follows: NK4-M2GlyR-p22 (), 
NK4-M2GlyR-p22 S22W (), NK4-M2GlyR-p22 Q21R,S22W(∆), NK4-M2GlyR-p22 
T20R,S22W(), NK4-M2GlyR-p22 T19R, S22W () and NK4-M2GlyR-p22 Q21W, S22R(◊).  
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Mr (Da) Sol.(mM) n 
IMAX 
(μA/cm2) k1/2 (μM) 
KKKKPARVGLGITTVLTMTTQS none 2358.9 11.1 1.9 ± 0.6 23.7 ± 5.6 210 ± 70 
KKKKPARVGLGITTVLTMTTQW S22W 2458.0 1.9 5.4 ± 2.9 13.0 ± 1.0 45 
KKKKPARVGLGITTVLTMTTRW Q21R, 
S22W 




2513.1 5.2 2.3 ± 0.8 22.7 ± 2.7 87 ± 15 
Table 3. Characterization of M2GlyR derived peptides with W and R substitutions. 
Introduction of a W in the presence and absence of the added R had a dramatic effect on the 
concentration required for half-maximal ion transport activity. The left-shifted k1/2 values 
ranged from 36 to 87 μM as compared with the 210 μM observed for NK4-M2GlyR-p22. 
Three of the doubly substituted sequences exhibited similar left shifts in the k1/2 for anion 
transport when compared to NK4-M2GlyR-p22 S22W. NK4-M2GlyR-p22 T20R, S22W did 
not show this dramatic left-shift. The simplest interpretation is that the sequences with left-
shifted k1/2 values form homo-oligomeric supramolecular assemblies at lower concentrations 
than the benchmark peptide.  
With regard to IMAX, the doubly substituted sequences exhibited greater maximal transport 
rates relative to either NK4-M2GlyR-p22 or C-terminal W substituted NK4-M2GlyR-p22 
S22W peptides. In the doubly substituted sequences the position of the R relative to the W 
also had an effect on IMAX. The sequences which introduced R at positions 20 or 21, exhibited 
a greater IMAX (22.7  2.7 and 26.2  3.2 µAcm-2, respectively) than was observed with the W 
alone substituted sequence. These IMAX values are similar to that seen for M2GlyR-p22. 
Introduction of the R at position 19 and inverting the R - W pair of sequence NK4-M2GlyR-
p22 Q21R, S22W to W - R resulted in even larger IMAX values of 33.7  1.3 and 33.6  2.2 
µAcm-2, respectively. Most importantly, R substituted sequences showed greatly enhanced 
efficacy with ISC values equaling IMAX for M2GlyR-p22 with concentrations at or below 50 
μM. The sum effect of changes in the kinetic parameters (IMAX and k1/2) is a substantial 
reduction in the peptide concentration required to attain ion transport rates that will likely 
be relevant in future basic and applied applications. With the exception of NK4-M2GlyR-p22 
T20R, S22W all of the other W and R containing sequences have greater Hill coefficients (3.3 
± 1.6 to 5.4 ± 2.9) than that calculated for NK4-M2GlyR-p22 (2.1 ± 0.8). M2GlyR-p22 T20R, 
S22W had a Hill coefficient (2.8 ± 0.8) similar to that seen with NK4-M2GlyR-p22. The 
increase in the Hill coefficients to values approaching five suggests that 
association/dissociation mechanisms in the bilayer are sensitive to structural changes in the 
peptide and consistent with the prediction that the channel pore is a homo-oligomeric 
supramolecular assembly that assembles by a complex or multistep mechanism. 
As assessed in the Ussing chamber experiments, reintroduction of an R near the C-terminus 
in conjunction with the added W contributes another factor that influences the minimum 
concentrations required for assembly of a functional channel. Introduction of an R at, at any 
of the tested positions slightly decreases the Hill coefficient, suggesting that there is an 
energetic cost in forcing the R (transiently) across the acyl core of the phospholipids. Placing 
R either at position 19 or just outside the membrane appears to be optimal with regard to 
IMAX, while an R placed at position 21 appears to be optimal with regard to k1/2. Placing R at 
position 20 seems to be the least optimal position since the Hill coefficient, k1/2 and IMAX 
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show the lowest values within this peptide series. Computer modeling studies indicated 
that the R in any of the internal C-terminal positions could snorkel back toward the 
membrane to form a second membrane anchor. There is no evidence that the R in any of 
these substituted peptides is positioned with the side chain pointed into the water-filled 
lumen of the assembled pore.  
In a parallel set of experiments designed to assess the role of the indole group in altering n, 
IMAX and k1/2 values (Derived from Fig. 17 and summarized in Table 4), sequences were 
prepared that replaced the W with either F or Y. The F or Y substituted sequences, which 
also contain a second R substitution, exhibited greater solubility compared to their W-
containing counterparts, with the exception of NK4-M2GlyR-p22 Q21F, S22R. All of the 
aromatic amino acid containing sequences had lesser amounts of higher molecular weight 
associations in aqueous environments compared to the aromatic-free sequence. 
Predominantly monomer, with some dimer, is present in the cross-linked aromatic 
sequences.  
 
Fig. 17. Concentration-dependence of ISC induced by NK4-M2GlyR-p22 derived peptides 
with either F or Y and W amino acid substitutions on MDCK epithelial monolayers. 
Symbols represent the mean and standard error of 4 or greater observations for each 
concentration tested. Solid lines represent the best fit of a modified Hill equation to each 
data set. The NK4-M2GlyR derived peptides dose dependent ISC curves are as follows: NK4-
M2GlyR-p22 (), NK4-M2GlyR-p22 Q21W, S22R (◊), NK4-M2GlyR-p22 Q21R, S22F (*), NK4-
M2GlyR-p22 T19R, S22F (closed hexagon), NK4-M2GlyR-p22 Q21F, S22R (), NK4-M2GlyR-
p22 Q21R, S22Y (open hexagon) and NK4-M2GlyR-p22 T19R, S22Y ().  
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Mr (Da) Sol.(mM) n 
IMAX 












2447.1 21.0 3.1 ± 0.6 31.8 ± 3.6 120 ± 10 
Table 4. Characterization of M2GlyR derived peptides with F/Y and R Substitutions. 
The secondary structures of these peptides were measured in SDS micelles. CD spectra 
contained minima at 208 and 222 nm, similar to those seen for all other sequences, which 
indicate predominantly helical structures. Considering the lack of solution aggregation 
and similar CD profiles, we concluded that these sequences formed a similar hydrophobic 
fold (in solution) that prevents association or aggregation in aqueous solution, similar to 
that described above for other structures. In addition to stabilizing the concentration of 
monomer in aqueous solutions, inclusion of any C-terminal aromatic residue provided a 
lipid/water interfacial anchor. As was seen with W, F residues are commonly present 
(and Y to a lesser extent) at the hydrophobic/hydrophilic interface for TM segments of 
membrane proteins (Braun and von Heijne, 1999; Mall et al., 2000; Demmers et al., 2001; 
de Planque et al., 2003; Granseth et al., 2005; van der Wel et al., 2007; Hong et al., 2007).  
The data for sequences NK4-M2GlyR-p22 and NK4-M2GlyR-p22 Q21W, S22R are included 
as reference values. Comparing the F substituted sequences to those containing the paired 
W, the F-containing peptides displayed similar IMAX but have right-shifted k1/2 values. The 
Y variants gave mixed results relative to their W counterparts. NK4-M2GlyR-p22 Q21R, 
S22Y showed a higher IMAX, but had a right-shifted k1/2 value while sequence NK4-
M2GlyR-p22 T19R, S22Y was inferior in both respects. With the exception of NK4-
M2GlyR-p22 Q21R, S22F, the k1/2 values for the Y and F containing peptides are right-
shifted relative to the W-containing peptides but left-shifted relative to the unmodified 
M2GlyR-p22.  
Comparing all of the summarized data in Tables 3 and 4 and the profiles shown in Figs. 16 
and 17, the sequences displaying the highest ion transport activity and the second and third 
most left-shifted k1/2 values are both W containing peptide sequences, NK4-M2GlyR-p22 
T19R, S22W and NK4-M2GlyR-p22 Q21W, S22R. Based on the concentrations required for 
k1/2, a rank ordering of the assembly-promoting effects of the C-terminal aromatic 
substitutions are as follows W > F >>Y. Given that when the R is placed at the C-terminus in 
NK4-M2GlyR-p22 Q21W, S22R will most likely cause further thinning of the membrane 
upon insertion (see Fig. 17), the sequence NK4-M2GlyR-p22 T19R, S22W was chosen as a 
lead sequence for further analysis and modification.  
Before committing to in vivo animal studies and preclinical trials, a few questions had to be 
addressed—did the lysine adduction and amino acid substitutions at T19R and S22W of the 
peptide alter its selectivity as an anion channel and did these modifications generate a 
potentially immunogenic structure?  
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NK4-M2GlyR-p22 T19R, S22W was administered at clinically relevant dosages to the nasal 
passages of specific-pathogen-free female C57/BL6 mice to test for the induction of an 
immune response with or without cholera toxin (CT) a strong mucosal adjuvant. 
Lipopolycaccharide (LPS)-free peptide, when administered alone, induced very little peptide-
specific immunity based on analyses of peptide-specific antibodies by enzyme-linked 
immunosorbent and enzyme-linked immunospot assays, induction of cytokine production, 
and delayed-type hypersensitivity (DTH) responses. The administration of NK4-M2GlyR-p22 
T19R, S22W with CT induced peptide-specific immunoglobulin G (IgG) antibodies, DTH 
responses and a Th2-dominant cytokine response. Co-administration of CT induced a systemic 
NK4-M2GlyR-p22 T19R, S22W-specific IgG response but not a mucosal peptide-specific 
antibody response. The lack of peptide-specific immunity and specifically mucosal immunity 
should allow repeated NK4-M2GlyR-p22 T19R, S22W peptide applications to epithelial 
surfaces to correct ion channelopathies (van Ginkel et al., 2008). 
Results indicate that additional modifications are necessary to achieve the desired anion 
selectivity. NK4-M2GlyR-p22 T19R, S22W was tested in artificial bilayers composed of 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine:1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-L-serine (POPC:POPS, 70:30) and in Xenopus oocytes. In both cases the selectivity for 
monovalent anions relative to monovalent cations had dropped to a value slightly above 
unity, indicating that the pore formed was only slightly anion selective. Computer simulations 
were employed as an initial strategy to determine the most promising structures for synthesis 
and testing. Before those simulations could be conducted, the identity of the pore-forming 
residues had to be established. The structure of NK4-M2GlyR-p22 T19R, S22W was analyzed 
by solution NMR as a monomer in detergent micelles and simulated as five-helix bundles in a 
membrane environment. Details of helix packing and residue distribution of the pore were 
analyzed. Results summarized in Fig. 18a demonstrate that the pore is mainly lined with A6, 
R7, L10, T13, T14, T17, T20 and Q21. Note the N- and C-terminal residues, K1-4 and W22, 
should not be considered as pore lining, even though they are indicated to have high pore-
lining probabilities based on their contacts with (bulk) water molecules. The predicted pore-
lining interface is largely consistent with the one derived from consideration of 
amphipathicity. However, the predicted pore-lining interface is broader due to substantial 
fluctuations of the pore. Participation of residues in helix-helix packing is characterized by 
calculating the average burial areas of side-chains, shown in Fig. 18b. Clearly, most residues 
with the structured region contribute to helix-helix interactions, except G9, G11, I12, V15 and 
R19. These residues either lack side chains (G9 and G11) or are fully membrane exposed. (I12, 
V15, L16 and R19). L10 and Q21 appear to be particularly important for stabilization of the 
pore assembly with the largest buried surface areas. Ongoing studies are guided by the 
hypothesis that alterations in one or more of the following parameters-- hydrogen bonding 
potentials of pore lining residues, electrostatics of pore lining residues, pore length or pore 
rigidity--will affect anion selectivity. By defining which of these elements increase selectivity 
we will elucidate how selectivity filters and permeation rates might be modulated so that an 
optimal sequence to allow for highly-selective Cl- permeation can be developed. Current 
experiments are designed to examine the effect of adding the positively charged amino acid L-
diaminopropionic acid (DAP; R= CH2-+NH3). Computer Modeling studies were performed on 
both singly and doubly DAP-substituted sequences (Fig. 19). Modeling the Potential of Mean 
Force (PMF) for moving different ions from one side of the channel to the other predicted 
similar permeabilities through NK4-M2GlyR-p22 T19R, S22W for both Cl- and Na+, while 
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introduction of the cationic DAP residues favored the passage of Cl-. The double-substituted 
T13Dap, T20Dap sequence shows the smallest energy wells where Cl- could become trapped, 
suggesting that it could be a preferred sequence. 
 
Fig. 18. a. Probabilities of a residue being either a pore-lining one or a membrane-exposed 
one. b. Average surface area of burial due to peptide-peptide interactions. The results are 
calculated from the last 80 ns of 100 ns production simulation of the left-handed channel. 
 
Fig. 19. Summary of the preliminary simulations of NK4-M2GlyR-p22 T19R, S22W (lane 1) 
and its several singly (lane 2, T17Dap) and doubly Dap substituted sequences (lane 3, 
T13Dap,T17Dap; lane 4, T13Dap,T20Dap). The lengths of the simulations are at least 20 ns. 
The pore profiles were computed using the HOLE program based on the last snapshots 
shown. The PMFs were computed from equilibrium ion densities. The red line signifies 
chloride and the green line sodium. 
www.intechopen.com
 
Channel Replacement Therapy for Cystic Fibrosis 
 
325 
Surprisingly, in generating more cationic channel-forming sequences, assembly, as assessed 
in silico, was not hampered by the presence of inter-peptide charge repulsion between the 
amino groups on adjacent helical segments. This repulsion appears to be accommodated by 
a widening of the pore. It might also cause the helices to adopt a staggered registry; 
however, these modeling studies have not indicated that outcome. Computer modeling of 
the M2GlyR-p22 T19R, S22W pore predicts the diameter to be about 4-5 Å at the narrowest 
portion of the channel (position T17). As stated above, modeling indicates that widening of 
the pore by the introduction of cationic residues results in a shift of the narrowest part of the 
pore to L10 with about the same pore diameter. The sequences containing multiple DAP 
residues appear to increase the diameter of the pore to ~8 Å, potentially leading to the 
passage of larger anions that were previously impermeable (glutamate, isethionate, etc.) 
and/or increased conductance. Preliminary results indicate that all of the DAP substituted 
sequences generate ion fluxes both across MDCK monolayers and in Xenopus oocytes. 
Permselectivity, however, remains to be determined. 
NK4-M2GlyR p-22 peptides with both W and R substitutions near the C terminus appear to 
be optimal structures for ongoing development of a therapeutic agent. These structures 
exhibited the greatest net ion flux and were among the most potent of the peptides assessed. 
Importantly, a mucosal immune response was not observed following exposure to these 
structures. The greatest challenge for ongoing development is the establishment of high 
anion to cation selectivity. Pore and lipid interfacial side chains have been identified to 
provide key information that is being used to build new structures in silico. These new 
structures are now being tested for ion throughput and selectivity. In addition to developing 
a potentially therapeutic structure, the outcomes of these experiments will provide a wealth 
of information regarding the contributions of hydrogen bonding, electrostatics, and pore 
rigidity to ion selectivity. 
5. Summary 
Nearly seventy-five years have passed since cystic fibrosis of the pancreas was first described 
as a unique clinical syndrome that was associated with failure to thrive and death in early 
childhood. The underlying cause of the disease, the absence of an epithelial anion 
conductance, was determined in the early 1980s and the gene coding for this anion channel 
was identified by the end of that decade. Even though the underlying cause has been known 
for more than twenty years, a curative treatment has not been developed, even at the tissue or 
organ level. Through the years, numerous therapies have been implemented – some with more 
positive outcomes than others. The commonality of all therapies is their palliative nature – 
there is no cure for CF although there are promising therapies in the pipeline for some subsets 
of the patient population (e.g., VX-770 for patients harboring G551D mutations). Supplemental 
pancreatic enzymes, more potent antibiotics and targeted delivery systems, daily respiratory 
therapy and the use of anti-inflammatory agents have added years to the typical lifespan and 
have greatly enhanced the quality of life of those suffering from CF. Nonetheless, additional 
therapeutic options are needed to address both tissue-specific and generalized disease 
progression. A synthetic anion-selective channel that can be delivered directly to epithelial cell 
membranes will provide one such option for improved health. 
This line of investigation has as its primary goal to create a therapeutic channel-forming 
peptide that can be delivered from aqueous solution, insert itself into cell membranes and 
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provide a pathway that is selective for the permeation of anions. The synthetic peptide 
should be effective at low aqueous concentrations, persistent in the membrane, and should 
not be antigenic. A particular benefit of this approach is that the therapy could be effective 
independent of the genetic mutation(s) expressed by each patient. 
The development of synthetic channel-forming peptides has progressed through a series of 
stages including discovery, initial implementation or proof of concept, and optimization for 
various physical, biochemical and physiological endpoints. The glycine receptor, a naturally 
occurring anion selective channel, was selected as the simplest chassis from which to start 
the process. The M2 segment, which constitutes the pore of the pentameric receptor, was 
used to demonstrate that exogenously applied peptides could support anion movement 
across an epithelium. This peptide was modified with the addition of lysine residues to 
increase aqueous solubility and a truncated version was found to be equally effective, which 
reduced a portion of the burden of peptide synthesis. The truncated version was further 
modified to establish an anchor at the membrane:water interface. Together, these 
modifications yielded a peptide that is effective at aqueous concentrations below 50 
micromolar and that persists in the epithelium for hours. At various stages in this project, 
results have shown that the peptides have the desired effects on electrophysiology when 
tested in murine nasal epithelia and the peptides appear not to induce a mucosal immune 
response, even when administered with cholera toxin as an adjuvant. Although the 
underlying mechanism remains to be determined, channel forming peptides were also 
associated with an increase in glutathione release from CF cells, which also constitutes a 
therapeutic outcome. Overall, the line of investigation has yielded much new knowledge 
regarding the design and construction of ion channels. Ongoing studies are focused to 
modify the ion selectivity of the channel, i.e., to build an anion selective channel for 
therapeutics and to determine the contribution of structural elements to channel ion 
selectivity. Clearly, there continues to be a need for new and novel therapies to treat the 
many aspects of CF. Synthetic anion selective channels constitute a therapeutic modality 
that has great potential to improve the lives of these patients. 
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